主要文件

查看所有文档

A5605

苯磺酸氨氯地平

Name: 苯磺酸氨氯地平
Brand: SIGMA

≥98% (HPLC), L-type calcium channel blocker, powder

别名:

2-[(2-氨基乙氧基)-甲基]-4-(2-氯苯基)-1,4-二氢-6-甲基-3,5-吡啶二甲酸 3-乙基 5-甲酯苯磺酸酯, 活络喜(抗高血压药)

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₀H₂₅ClN₂O₅ · C₆H₅SO₃H

化学文摘社编号:

111470-99-6

分子量:

567.05

UNSPSC Code:

12352200

PubChem Substance ID:

24890999

NACRES:

NA.77

MDL number:

MFCD00887594

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

苯磺酸氨氯地平, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: ≥20 mg/mL

SMILES string

OS(=O)(=O)c1ccccc1.CCOC(=O)C2=C(COCCN)NC(C)=C(C2c3ccccc3Cl)C(=O)OC

InChI

1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)

InChI key

ZPBWCRDSRKPIDG-UHFFFAOYSA-N

Gene Information

human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779)

说明

Application

苯磺酸氨氯地平是一种 L 型钙通道阻滞剂，可用于治疗心绞痛和高血压。氨氯地平还可抑制人表皮样癌细胞 A431 的生长，并对雄性大鼠具有抗生殖作用。

Biochem/physiol Actions

氨氯地平是一种 L 型钙通道阻滞剂。氨氯地平属于一类心血管药物，作用于 Ca _V 1 或 L 型的电压门控钙通道。氨氯地平还具有降压和抗心绞痛作用。其活性主要存在于 (-)-异构体中。氨氯地平抑制人表皮样癌细胞 A431 的生长，对雄性大鼠有抗生殖作用。

苯磺酸氨氯地平是一种 L 型钙通道阻滞剂。

Features and Benefits

该化合物在受体分类和信号转导手册的钙通道页面上有重点介绍。如需浏览其他手册页面，请点击此处。

Still not finding the right product?

Explore all of our products under 苯磺酸氨氯地平

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Calcium Channels

We offers many products related to calcium channels for your research needs.

钙通道

我们提供多种与钙通道相关的产品以满足您的各类研究需求。

Reduced Lymphatic Function Predisposes to Calcium Channel Blocker Edema: A Randomized Placebo-Controlled Clinical Trial.

Sheyanth Mohanakumar et al.

Lymphatic research and biology, 18(2), 156-165 (2019-08-21)

Background: The current belief is that the calcium channel blocker (CCB)-induced edema is due to a preferential arterial over

Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.

Dean J Kereiakes et al.

Journal of clinical hypertension (Greenwich, Conn.), 14(3), 149-157 (2012-03-01)

J Clin Hypertens (Greenwich). 2012;14:149-157. ©2012 Wiley Periodicals, Inc. Most patients with hypertension require combination therapy in order to achieve blood pressure (BP) goals. This 40-week open-label extension of the 12-week double-blind Triple Therapy With Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide

The effect of renin-angiotensin-aldosterone system inhibitors on organ-specific ace2 expression in zebrafish and its implications for COVID-19.

Gha-Hyun J Kim et al.

Scientific reports, 11(1), 23670-23670 (2021-12-10)

Among cases of SARS-CoV-2 infections that result in serious conditions or death, many have pre-existing conditions such as hypertension and are on renin-angiotensin-aldosterone system (RAAS) inhibitors. The angiotensin-converting-enzyme-2 (ACE2), a key protein of the RAAS pathway, also mediates cellular entry

查看所有相关文献

全球贸易项目编号

货号	GTIN
A5605-10MG	04061833376102
A5605-50MG	04061833376119